Home › Funds › Bellevue Group AG › ORKA
Bellevue Group AG position in ORKA
ORUKA THERAPEUTICS INC · Health Care
Bellevue Group AG reported holding 1,641,059 shares of ORKA (ORUKA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$136.7M, representing 2.84% of its reported portfolio and ranking #9 among its reported holdings. Bellevue Group AG has disclosed ORKA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's ORKA position evolved
Bellevue Group AG first disclosed a stake in ORKA in Q1 2026 at 507,008 shares (US$24.9M). The position peaked in Q2 2026 at 1,657,190 shares, worth US$157.7M. Across 3 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,641,059 shares valued at US$136.7M — a reduction of -16,131 shares quarter over quarter.. Notable position changes include a 227% increase in Q2 2026 (shares fell 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 507.01K | $24.87M | New |
| Q2 2026 | 1.66M | $157.71M | Add |
| Q3 2026 | 1.64M | $136.68M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ORKA and 13F data
ORKA (ORUKA THERAPEUTICS INC) is a Health Care company. 73 other funds we track also report a position in ORKA — the largest reported positions include Venrock Adviser, LLC (US$345.5M), Fairmount Funds Management LLC (US$308.6M), RTW INVESTMENTS, LP (US$261.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ORKA
- Venrock Adviser, LLC 4.15M sh · $345.52M · Q3 2026
- Fairmount Funds Management LLC 3.71M sh · $308.61M · Q3 2026
- RTW INVESTMENTS, LP 3.14M sh · $261.45M · Q3 2026
- Paradigm Biocapital Advisors LP 2.49M sh · $207.68M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 1.55M sh · $129.48M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.07M sh · $89.32M · Q3 2026
- Deep Track Capital, LP 1.07M sh · $89.10M · Q3 2026
- Remedium Capital Partners, LLC 954.15K sh · $79.47M · Q3 2026
- Avidity Partners Management LP 785.42K sh · $65.42M · Q3 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 723.92K sh · $60.30M · Q3 2026
- Affinity Asset Advisors, LLC 600.00K sh · $49.97M · Q3 2026
- Cormorant Asset Management, LP 400.00K sh · $33.32M · Q3 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held ORKA?
Bellevue Group AG has disclosed ORKA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Bellevue Group AG's current position in ORKA?
As of Q3 2026, Bellevue Group AG holds 1.64M shares of ORKA (ORUKA THERAPEUTICS INC), valued at $136.68M, representing 2.84% of its reported portfolio and ranking #9.
Has Bellevue Group AG been buying or selling ORKA?
In the latest 13F filing (Q3 2026), Bellevue Group AG reduced its position in ORKA. The position peaked in Q2 2026 at 1.66M shares.
Which other funds hold ORKA?
Other major institutional holders of ORKA include Venrock Adviser, LLC, Fairmount Funds Management LLC, RTW INVESTMENTS, LP, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.